Alvaro R. B. Prieto da Silva

Dr. Alvaro R. B. Prieto da Silva

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ATAlba F. C. Torres
Alba F. C. Torres
CHChen Huang
Chen Huang
CCCheong-Meng Chong
Cheong-Meng Chong
SLSiu Wai Leung
Siu Wai Leung
ASAlvaro R. B. Prieto da Silva
Alvaro R. B. Prieto da Silva
Gandhi Rádis-BaptistaGandhi Rádis-Baptista
Gandhi Rádis-Baptista
Dinoponera quadriceps is a predatory giant ant that inhabits the Neotropical region and subdues its prey (insects) with stings that deliver a toxic cocktail of molecules. Human accidents occasionally occur and cause local pain and systemic symptoms. A comprehensive study of the D. quadriceps venom gland transcriptome is required to advance our knowledge about the toxin repertoire of the giant ant venom and to understand the physiopathological basis of Hymenoptera envenomation. We conducted a transcriptome analysis of a cDNA library from the D. quadriceps venom gland with Sanger sequencing in combination with whole-transcriptome shotgun deep sequencing. From the cDNA library, a total of 420 independent clones were analyzed. Although the proportion of dinoponeratoxin isoform precursors was high, the first giant ant venom inhibitor cysteine-knot (ICK) toxin was found. The deep next generation sequencing yielded a total of 2,514,767 raw reads that were assembled into 18,546 contigs. A BLAST search of the assembled contigs against non-redundant and Swiss-Prot databases showed that 6,463 contigs corresponded to BLASTx hits and indicated an interesting diversity of transcripts related to venom gene expression. The majority of these venom-related sequences code for a major polypeptide core, which comprises venom allergens, lethal-like proteins and esterases, and a minor peptide framework composed of inter-specific structurally conserved cysteine-rich toxins. Both the cDNA library and deep sequencing yielded large proportions of contigs that showed no similarities with known sequences. To our knowledge, this is the first report of the venom gland transcriptome of the New World giant ant D. quadriceps. The glandular venom system was dissected, and the toxin arsenal was revealed; this process brought to light novel sequences that included an ICK-folded toxins, allergen proteins, esterases (phospholipases and carboxylesterases), and lethal-like toxins. These findings contribute to the understanding of the ecology, behavior and venomics of hymenopterans.

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
IKIrina Kerkis
Irina Kerkis
MHMirian A. F. Hayashi
Mirian A. F. Hayashi
ASAlvaro R. B. Prieto da Silva
Alvaro R. B. Prieto da Silva
APAlexandre Pereira
Alexandre Pereira
PJPaulo Luiz De Sá Júnior
Paulo Luiz De Sá Júnior
TYTetsuo Yamane
Tetsuo Yamane
Animal venoms comprise a naturally selected cocktail of bioactive peptides/proteins and other molecules, each of which playing a defined role thanks to the highly specific interactions with diverse molecular targets found in the prey. Research focused on isolation, structural, and functional characterizations of novel natural biologics (bioactive peptides/proteins from natural sources) has a long way to go through from the basic science to clinical applications. Herein, we overview the structural and functional characteristics of the myoneurotoxin crotamine, firstly isolated from the South American rattlesnake venom. Crotamine is the first venom peptide classified as a natural cell penetrating and antimicrobial peptide (CPP and AMP) with a more pronounced antifungal activity. In contrast to other known natural CPPs and AMPs, crotamine demonstrates a wide spectrum of biological activities with potential biotechnological and therapeutic values. More recent studies have demonstrated the selectivein vitroanticancer activity of crotamine.In vivo, using a murine melanoma model, it was shown that crotamine delays tumor implantation, inhibits tumor cells proliferation, and also increases the survival of mice engrafted with subcutaneous melanoma. The structural and functional properties and also the possible biotechnological applications of minimized molecules derived from crotamine are also discussed.

1 July 2012 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
SPSteve Peigneur
Steve Peigneur
DODiego J. B. Orts
Diego J. B. Orts
ASAlvaro R. B. Prieto da Silva
Alvaro R. B. Prieto da Silva
NONancy Oguiura
Nancy Oguiura
MBMalvina Boni-Mitake
Malvina Boni-Mitake
JTJan Tytgat
Jan Tytgat
Crotamine, a 5-kDa peptide, possesses a unique biological versatility. Not only has its cell-penetrating activity become of clinical interest but, moreover, its potential selective antitumor activity is of great pharmacological importance. In the past, several studies have attempted to elucidate the exact molecular target responsible for the crotamine-induced skeletal muscle spasm. The aim of this study was to investigate whether crotamine affects voltage-gated potassium (KV) channels in an effort to explain its in vivo effects. Crotamine was studied on ion channel function using the two-electrode voltage clamp technique on 16 cloned ion channels (12 KV channels and 4 NaV channels), expressed in Xenopus laevis oocytes. Crotamine selectively inhibits KV1.1, KV1.2, and KV1.3 channels with an IC50 of ∼300 nM, and the key amino acids responsible for this molecular interaction are suggested. Our results demonstrate for the first time that the symptoms, which are observed in the typical crotamine syndrome, may result from the inhibition of KV channels. The ability of crotamine to inhibit the potassium current through KV channels unravels it as the first snake peptide with the unique multifunctionality of cell-penetrating and antitumoral activity combined with KV channel-inhibiting properties. This new property of crotamine might explain some experimental observations and opens new perspectives on pharmacological uses.

28 July 2011 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
APAlexandre Pereira
Alexandre Pereira
AKAlexandre Kerkis
Alexandre Kerkis
MHMirian Af Hayashi
Mirian Af Hayashi
APAparecida Sp Pereira
Aparecida Sp Pereira
FSFernando S Silva
Fernando S Silva
IKIrina Kerkis
Irina Kerkis
Objectives: Selective anticancer cell activity for both cell-penetrating and cationic antimicrobial peptides has previously been reported. As crotamine possesses activities similar to both of these, this study investigates crotamine's anticancer toxicity in vitro and in vivo. Research design and methods: In vitro cancer cell viability was evaluated after treatment with 1 and 5 μg/ml of crotamine. In vivo crotamine cytotoxic effects in C57Bl/6J mice bearing B16-F10 primary cutaneous melanoma were tested, with two groups each containing 35 mice. The crotamine-treated group received 1 μg/day of crotamine per animal, subcutaneously which was well tolerated; the untreated group received a placebo. Results: Crotamine at 5 μg/ml was lethal to B16-F10, Mia PaCa-2 and SK-Mel-28 cells and inoffensive to normal cells. In vivo crotamine treatment over 21 days significantly delayed tumor implantation, inhibited tumor growth and prolonged the lifespan of the mice. Mice in the crotamine-treated group survived at signifi...

1 March 2009 in Toxicon
Verified
Journal Article
Closed access
MNMárcia Neiva
Márcia Neiva
FAFabricio B.M. Arraes
Fabricio B.M. Arraes
JSJonso Vieira de Souza
Jonso Vieira de Souza
Gandhi Rádis-BaptistaGandhi Rádis-Baptista
Gandhi Rádis-Baptista
ASAlvaro R. B. Prieto da Silva
Alvaro R. B. Prieto da Silva
SASpartaco Astolfi-Filho
Spartaco Astolfi-Filho

1 July 2001 in Toxicon
Verified
Journal Article
Closed access
ASAlvaro R. B. Prieto da Silva
Alvaro R. B. Prieto da Silva
IYIvone Kasuko Yamagushi
Ivone Kasuko Yamagushi
JMJosefina Farina Morais
Josefina Farina Morais
HHHisako Gondo Higashi
Hisako Gondo Higashi
IRIsaı́as Raw
Isaı́as Raw
JOJane Silveira de Oliveira
Jane Silveira de Oliveira